Managed Account Advisors’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Managed Account Advisors’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$20K	Sell	408 -23	-5%	-$1.38K	﹤0.01%	2803
2015 Q1	$34K	Sell	431 -6,022	-93%	-$374K	﹤0.01%	2672
2014 Q4	$391K	Buy	6,453 +3,070	+91%	+$154K	﹤0.01%	2244
2014 Q3	$144K	Buy	3,383 +53	+2%	+$2.85K	﹤0.01%	2343
2014 Q2	$206K	Sell	3,330 -743	-18%	-$43.2K	﹤0.01%	2294
2014 Q1	$264K	Buy	4,073 +1,014	+33%	+$68.6K	﹤0.01%	2201
2013 Q4	$172K	Sell	3,059 -238	-7%	-$13.4K	﹤0.01%	2231
2013 Q3	$202K	Sell	3,297 -2,354	-42%	-$159K	﹤0.01%	2143
2013 Q2	$331K	Buy	+5,651	New	+$348K	﹤0.01%	2088

Other funds holding OREX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Managed Account Advisors's OREX Position: Q2 2015 in Review

Managed Account Advisors reduced its Orexigen Therapeutics, Inc. (OREX) stake by 5.3% in Q2 2015, selling an estimated $1.38K and leaving 408 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #2803.

Managed Account Advisors first reported a position in OREX in Q2 2013 and has held it in 9 quarters since. The position peaked at $391K in Q4 2014. 161 funds tracked by Wall St. Rank hold OREX as of Q2 2015.

Managed Account Advisors held 408 shares of Orexigen Therapeutics, Inc. worth $20K as of Q2 2015.
Managed Account Advisors sold 23 Orexigen Therapeutics, Inc. shares in Q2 2015, an estimated $1.38K.
Orexigen Therapeutics, Inc. made up ﹤0.01% of Managed Account Advisors's portfolio in Q2 2015, its #2803 holding.
Managed Account Advisors first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and has held it in 9 quarters since.
Managed Account Advisors's Orexigen Therapeutics, Inc. position peaked at $391K in Q4 2014.
161 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.